{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'Total transcriptome analysis', 'mRNA expression of lesional skin will be analyzed by total mRNA sequencing. Respective skin', 'biopsy samples (2 lesional 4 mm biopsies) will be taken at baseline (before treatment) and', 'after 20 weeks of treatment.', 'Specific mRNA quantification', 'The mRNA expression of markers, such as e.g. IL-23 p19, IL-17A, CXCL (CXC Motif', 'Chemokine) 8, \u00df-defensin 2, will be individually quantified by real-time polymerase chain', 'reaction on reverse transcribed mRNA (qPCR) lesional skin.', 'Samples will be taken at the following time points: baseline (before treatment) and after 20', 'weeks of treatment.', 'Immunohistochemistry', 'The number of immune cells, such as T cells will be quantified by immunohistochemistry of', 'lesional skin.', 'Samples will be taken at the following time points: baseline (before treatment) and after 20', 'weeks of treatment.', '12.2 Safety Assessments', '12.2.1 Adverse Events (AE)', 'The investigator will assess and record any AEs (for definition, see Section 13.1) starting from', 'baseline in detail including the date of onset, intensity, relationship of the AE to study drug,', 'action(s) taken, seriousness, time course, duration and outcome. All AEs with onset from visit', '2 are to be reported on the AE page of the CRF with complete information as required (see', 'Section 13.2). If AEs occur, the main concern will be the safety of the study patients. At time', 'of the informed consent signature, each patient must be given the name and phone number of', 'investigation site personnel for reporting AEs and medical emergencies.', '12.2.2 Pregnancy Test', 'A urine pregnancy test will be performed for female patients of childbearing potential at the site', 'at all visits.', '12.2.3 Physical Examination and Vital Signs', 'The physical examination will include the determination of height and weight.', 'If indicated based on the symptoms or medical history, additional exams will be performed at', 'the discretion of the investigator.', 'Information for all physical examinations must be included in the source documentation.', 'Significant findings that are present prior to enrolment must be included in the medical history', 'on the CRF. Serious findings made after ICF signature which meet the definition of an SAE', 'must be recorded as SAE.', 'Evaluation of vital signs will be performed after 10 minutes resting. Assessments should be', 'performed by the same person throughout the study.', 'Page 44 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'Pulse rate and blood pressure will be measured on the same arm on each occasion with the', 'patient sitting. These data will be recorded in the CRF.', 'Blood pressure (systolic / diastolic) will be measured with a mercury manometer or an', 'automated device (same type of device for all measurements). Normal blood pressure will be', 'defined as a systolic pressure of 90 - 120 mmHg and diastolic pressure of 60 - 80 mmHg.', 'Notable blood pressure will be hypertension (systolic pressure >140 mmHg and / or diastolic', 'pressure >90 mmHg) or hypotension (systolic pressure <90 mmHg and / or diastolic pressure', '<60 mmHg). A blood pressure indicative of prehypertension (systolic pressure 120', '-', '140 mmHg and / or diastolic pressure 80 - 90 mmHg) will not be regarded as notable according', 'to the seventh report of the Joint National Committee on Prevention, Detection, Evaluation,', 'and Treatment of High Blood Pressure (34).', 'A normal pulse rate will be defined as a rate of 60 - 100 beats per minute. Notable pulse rates', 'are a rate above 100 bpm (tachycardia) and under 60 bpm (brachycardia).', 'Whether action needs to be taken to address notable vital signs will be decided by the', 'investigator, taking into account the overall status of the patient. No specific action is foreseen', 'as part of the study protocol.', '12.3 Demographics and Baseline Characteristics', 'Demographics and Baseline Characteristics consist of those parameters that are assessed', 'only at screening / baseline.', '12.3.1 Patient Demography', 'Patient demography consists of:', 'Age at screening', 'Height', 'Weight', 'Race', 'Sex', 'Educational status', '12.3.2 Medical History', 'The medical history will be obtained by asking the patient or by inspecting his / her medical', 'records.', 'Any previous diseases within the last 3 months before screening and any concomitant', 'diseases will be documented in the CRF.', '12.3.3 Psoriasis History', 'For the documentation of the psoriasis history, the patient will be asked or his / her medical', 'records will be inspected for:', 'Page 45 of 75']\n\n###\n\n", "completion": "END"}